| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 02/05/2004 | WO2004011516A1 Novel compound having cholesterol lowering activity |
| 02/05/2004 | WO2004011470A1 Furoisoquinoline derivative and use thereof |
| 02/05/2004 | WO2004011469A1 Cell differentiation inductor |
| 02/05/2004 | WO2004011443A1 Pyrimidyl sulphone amide derivatives as chemokine receptor modulators |
| 02/05/2004 | WO2004011440A1 Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredint |
| 02/05/2004 | WO2004011438A1 Diaryl-substituted cyclic urea derivatives having an mch-modulatory effect |
| 02/05/2004 | WO2004011410A1 Chemical compounds |
| 02/05/2004 | WO2004011402A2 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | WO2004010995A1 Fused heteroaryl derivatives for use as p38 kinase inhibitors in the treatment of i.a. rheumatoid arthristis |
| 02/05/2004 | WO2004010992A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | WO2004010980A1 Compositions comprising hmg-coa reductase inhibitor |
| 02/05/2004 | WO2004010974A2 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | WO2004010973A2 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | WO2004010972A2 Pellicle-resistant gelatin capsule |
| 02/05/2004 | WO2004010953A2 Implantable artificial organ devices |
| 02/05/2004 | WO2004010945A2 Cyclooxygenase- 2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | WO2004010944A2 Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications |
| 02/05/2004 | WO2003096968A3 Oral osmotic controlled drug delivery system |
| 02/05/2004 | WO2003087818A3 Diagnostic and therapeutic use of kremen 1 and 2, inhibitors of the canonical wnt-signaltransduction |
| 02/05/2004 | WO2003084938A3 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases |
| 02/05/2004 | WO2003083442A3 Life sciences business systems and methods |
| 02/05/2004 | WO2003080608A3 Quinoline and aza-indole derivatives and their use as 5-ht6 ligands |
| 02/05/2004 | WO2003080580A3 Quinoline derivatives and their use as 5-ht6 ligands |
| 02/05/2004 | WO2003075857A3 Amino-methyl substituted tetracycline compounds |
| 02/05/2004 | WO2003074654A3 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 02/05/2004 | WO2003066091A3 Compositions and methods for modulation of effects on phagocyte and lymphoid cell populations employing tirc7 |
| 02/05/2004 | WO2003063849A9 Medicinal composition for diagnosis, prevention, or therapy of multiple risk factor syndrome |
| 02/05/2004 | WO2003055911A8 Cystine-knot fold protein |
| 02/05/2004 | WO2003042397A3 A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| 02/05/2004 | WO2002087555A3 Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer |
| 02/05/2004 | WO2002041834A8 Atorvastatin hemi-calcium form vii |
| 02/05/2004 | US20040025199 Comprises g-protein couple receptors for identifying modulators of g-protein activity and diagnosis and treatment of infections, nervous system, tumor, autoimmune and inflammatory disorders |
| 02/05/2004 | US20040024222 Such as 5-(4-(2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy)-benzo(b)thiophen-7 -ylmethyl)2,4-thiazolidinedione via bromo-/chloro-methylation; for treatment of diabetes |
| 02/05/2004 | US20040024216 HMG-CoA reductase inhibitors and method |
| 02/05/2004 | US20040024215 Such as 4'-trifluoromethyl-biphenyl-2-carboxylic acid(4-(4-(alpha-methyl-benzyl)-piperazin-1-yl)-phenyl)-amide; apoprotein B-100 (apoB-100) and microsomal triglyceride transfer protein (MTP) |
| 02/05/2004 | US20040024211 Such as (3S)-N-(2-(2-(2,4-dichlorophenyl)ethyl)-1-oxo-2,3-dihydro-1H-isoindol-5-yl) -3-methyl-N'-((1S,2S,3S,5R)-2,6,6-trimethylbicyclo(3.1.1)hept-3 -yl)piperazine-1-carboximidamide for treatment of obesity or type II diabetes |
| 02/05/2004 | US20040024210 New compounds |
| 02/05/2004 | US20040024197 Synthetic oligo- and polysaccharides exhibiting at least one covalent bond with biotin or a biotin derivative and having the anticoagulant and antithrombotic pharmacological activities of heparin |
| 02/05/2004 | US20040024179 Comprises peptide with heparin and/or lipopolysaccharide binding activity for use as treatment of endotoxic shock and endometriosis, anticoagulant, angiogenesis inhibitor, antiproliferative agent and contraceptive |
| 02/05/2004 | US20040024064 Determining risk for developing a fat metabolism disorder by comparing a sample Gs alpha expression level with that of the normal level; treating the disorder with a nucleic acid that codes a Gs alpha protein; prognosis; diagnosis; |
| 02/05/2004 | US20040024062 Inhibiting a condition mediated by the alpha v beta 3 or alpha v beta 5 integrin; antitumor, -metastasis, -arthritic agents; angiogenesis, inhibitors; osteoporosis, humoral hypercalcemia of malignancy, smooth muscle cell migration |
| 02/05/2004 | US20040024061 Solid compositions suitable for oral administration containing non-hygroscopic salts of l-carnitine and the alkanoyl l-carnitines with taurine chloride and glycine chloride |
| 02/05/2004 | US20040024060 Use of benzylideneaminoguanidines and hydroxyguanidines as melanocortin receptor ligands |
| 02/05/2004 | US20040024057 Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use related applications |
| 02/05/2004 | US20040024046 By precipitating the atorvastatin using a solvent of a second type from a solution of atorvastatin which is provided with a solvent of a first type |
| 02/05/2004 | US20040024040 Inhibitors of GSK-3 and uses thereof |
| 02/05/2004 | US20040024036 May take form of gel, ointment or emulsion for local administration, of transdermal patch or of film deposited by a spray, characterized in that it comprises at least one absorption promoter |
| 02/05/2004 | US20040024034 For modulating a peroxisome proliferator activated receptor, particularly in the treatment of diabetes mellitus |
| 02/05/2004 | US20040024027 5(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione hydriodide as pharmaceutical |
| 02/05/2004 | US20040024014 Such as 2-(nitrooxy)ethyl-2-(((3-methyl-4-(2,2,2-trifluoro-ethoxy)-2 -pyridyl)methyl)sulfinyl)benzimidazolecarboxylate; kits; for treating gastrointestinal disorders/ulcers |
| 02/05/2004 | US20040024002 Spirosubstituted piperidines as selective melanin concentrating hormone receptor antagonists for the treatment of obesity |
| 02/05/2004 | US20040023999 Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof |
| 02/05/2004 | US20040023992 Antiinflammatory agents |
| 02/05/2004 | US20040023989 Pyrazolo(4,3-c)piperidine and pyrazolo(4,3-d)pyrimidine derivatives |
| 02/05/2004 | US20040023974 Pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula I inhibit PTP-1B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present |
| 02/05/2004 | US20040023972 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS |
| 02/05/2004 | US20040023963 Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| 02/05/2004 | US20040023950 N-heterocyclic derivatives as NOS inhibitors |
| 02/05/2004 | US20040023947 Azepinoindole and pyridoindole derivatives as pharmaceutical agents |
| 02/05/2004 | US20040023945 Cyclic amp-specific phosphodiesterase inhibitors |
| 02/05/2004 | US20040023931 Method for maintaining a healthy bone structure by administering to a patient a bone health promoting effective amount of a medicament containing 1-amino-3-(N,N-dimethylamino)-propylidene-1,1-bisphosphonic |
| 02/05/2004 | US20040023923 Beta -Glucan which is cold-water soluble and is capable of forming a gel. The solubility is greater than 2% by weight in water at a temperature below approximately 50 degrees C. A process for preparing the beta -glucan by recovering the |
| 02/05/2004 | US20040023900 Derivatives of monosaccharides as cell adhesion inhibitors |
| 02/05/2004 | US20040023893 Coumarin derivatives for treatment of vascular disorders, skin disorders or allergies |
| 02/05/2004 | US20040023890 Drugs for diabetes |
| 02/05/2004 | US20040023885 Islet neogenesis therapy comprising an EGF and a gastrin in combination with immune suppression, and for treating or preventing early stage diabetes with a gastrin/CCK receptor ligand and an immunosuppressant are provided |
| 02/05/2004 | US20040023883 IGF-I and insulin variants are provided that selectively bind to IGFBP-1 or IGFBP-3. These agonist variants are useful, for example, to improve the half-lives of IGF-I and insulin, respectively. |
| 02/05/2004 | US20040023879 Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 |
| 02/05/2004 | US20040023871 Treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels. |
| 02/05/2004 | US20040023859 New melanocortin receptor ligands are cyclic peptide analogs that preferably exhibit selectivity for the MC-4 and/or the MC-3 receptors relative to the other melanocortin receptors |
| 02/05/2004 | US20040023854 Adiponectin and uses thereof |
| 02/05/2004 | US20040023840 Combination of organic compounds |
| 02/05/2004 | US20040023337 IL-13 mutein proteins, antibodies, compositions, methods and uses |
| 02/05/2004 | US20040022883 Persea americana var. drymifolia leaves (avocado) |
| 02/05/2004 | US20040022849 Oral pharmaceutical composition with controlled release and prolonged absorption |
| 02/05/2004 | US20040022834 Pharmaceutical oxan preparation |
| 02/05/2004 | US20040022783 Binding agents to CD23 |
| 02/05/2004 | US20040022781 Proteins and nucleic acids encoding same |
| 02/05/2004 | US20040022778 For therapy and prophylaxis of cardiovascular disease, strokes and myocardial infarction |
| 02/05/2004 | US20040022777 Fragments and antagonists of heat shock protein 60 |
| 02/05/2004 | DE10231370A1 Neue Thiophenglycosidderivate, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung Thiophenglycosidderivate new, processes for their preparation, pharmaceutical compositions containing them and their use |
| 02/05/2004 | CA2494668A1 Chemical compounds |
| 02/05/2004 | CA2494358A1 Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage |
| 02/05/2004 | CA2494102A1 Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient |
| 02/05/2004 | CA2494069A1 Pellicle-resistant gelatin capsule |
| 02/05/2004 | CA2494040A1 Multi-step method for the differentiation of insulin positive, glucose |
| 02/05/2004 | CA2493980A1 Gelatin capsule exhibiting reduced cross-linking |
| 02/05/2004 | CA2493924A1 Diaryl-substituted cyclic urea derivatives having an mch-modulatory effect |
| 02/05/2004 | CA2493913A1 Ppar alpha selective compounds for the treatment of dyslipidemia and other lipid disorders |
| 02/05/2004 | CA2493761A1 Compositions comprising hmg-coa reductase inhibitor |
| 02/05/2004 | CA2493755A1 Substituted indolealkanoic acids derivative and formulations containing same for use in treatment of diabetic complications |
| 02/05/2004 | CA2493751A1 Novel arylimidazole derivatives, preparation and therapeutic uses thereof |
| 02/05/2004 | CA2493156A1 Cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 02/05/2004 | CA2492463A1 Regulated aptamer therapeutics |
| 02/04/2004 | EP1386932A1 Improved humanized immunoglobulins |
| 02/04/2004 | EP1386930A1 Derivatives of exendin |
| 02/04/2004 | EP1386913A1 Pyrrole derivative |
| 02/04/2004 | EP1386908A1 Amine derivative with potassium channel regulatory function, its preparation and use |
| 02/04/2004 | EP1386905A1 Stable solution of reduced coenzyme q |
| 02/04/2004 | EP1386610A1 Medicament containing 2-HETE or 11,12-EET |